Cellectar

CLRB NASDAQ
2.180
+0.020
+0.93%
Opening 14:33 07/15 EDT
Open
2.180
Prev Close
2.160
High
2.200
Low
2.114
Volume
67.07K
Avg Vol (3M)
478.64K
52 Week High
12.76
52 Week Low
1.220
% Turnover
1.24%
Market Cap
11.76M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Cellectar CLRB stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
MORE >

Recently

Name
Price
%Change